# Cambrian Biopharma

> Cambrian Biopharma is a VC fund backing Biotechnology and Biopharma. See 8 investments, round sizes, portfolio and contact details. Updated Oct 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 8
- Last investment: Oct 2023
- Lead investor: 63%
- Last updated: Oct 2026
- LinkedIn: https://www.linkedin.com/company/cambrianbio/
- X (Twitter): https://twitter.com/cambrianbio
- Website: https://www.cambrianbio.com/

Cambrian Biopharma is a VC fund in New York focused on Biotechnology and Biopharma. Cambrian Biopharma is building the medicines that will modernize healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health.As a Distributed Development Company (or DisCo), Cambrian is advancing multiple scientific breakthroughs, each targeting a biological driver of aging. Our approach is todevelop interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life/overall quality of life as we age.

## Contacts

5 contacts available for Cambrian Biopharma. Shizune tracks 7 team members at Cambrian Biopharma. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/cambrian-biopharma?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 63% |
| Biopharma | 3 | 38% |
| Life Science | 3 | 38% |
| Medical | 2 | 25% |
| Health Care | 2 | 25% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 38% |
| Seed | 2 | 25% |
| Series B | 2 | 25% |
| Series C | 1 | 13% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Dennis Yamashita | Executive Vice President, Chemistry | 0 | https://shizune.co/investors/profile/dennis-yamashita |
| Adrienne Hallett | Vice-President of Global Policy | 0 | https://shizune.co/investors/profile/adrienne-hallett-0204 |
| Christian Angermayer | Co-Founder | 47 | https://shizune.co/investors/profile/christian-angermayer |
| Daisy Robinton | Scientist in Residence | 0 | https://shizune.co/investors/profile/daisy-robinton |
| James Peyer | Founder and CEO | 0 | https://shizune.co/investors/profile/james-peyer-269d |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Amplifier Therapeutics | Amplifier Therapeutics is a biopharmaceutical firm, developing AMP-activated protein kinase (AMPK) activator molecules to treat aging-related disorders such as metabolic problems, cardiovascular diseases, kidney diseases, and cancer. | $33.3M | Series A | Oct 17, 2023 | https://www.amplifier-tx.com |
| Vita Therapeutics | Vita Therapeutics is a cell engineering company that develops life-transformative treatments. Vita utilizes induced pluripotent stem cell technology to engineer specific cell types designed to replace those that are defective in patients. | $31M | Series B | Oct 12, 2022 | https://www.vitatx.com/ |
| Oviva Therapeutics | Oviva Therapeutics is a movement to improve women's experience of aging through biomedical research, development and advocacy. | $11.5M | Seed | May 19, 2022 | https://www.ovivatx.com/ |
| Vita Therapeutics | Vita Therapeutics is a cell engineering company that develops life-transformative treatments. Vita utilizes induced pluripotent stem cell technology to engineer specific cell types designed to replace those that are defective in patients. | $32M | Series A | Jun 23, 2021 | https://www.vitatx.com/ |
| Arcellx | Arcellx is a privately held development-stage company founded in 2015 and located in Montgomery County, Maryland. The Arcellx team is devoted to providing patients with superior immune cell therapies through scientific innovation, accelerated development, and responsible patient care. Although our initial clinical focus is cancer therapy, we arecommitted to extending our Antigen- Receptor Complex T cell (ARC-T) therapies across a broad spectrum of human disease. | $115M | Series C | Apr 13, 2021 | http://www.arcellx.com |
| Sensei Biotherapeutics | Sensei Biotherapeutics is a clinical-stage biotechnology company specializing in the field of next-generation cancer immunotherapies. The company developing novel biologics therapies targeting key components of the immune system for the treatment of cancers of unmet need. They are also focused on the discovery, development, and delivery ofmedicines that alter the treatment landscape and contributing value to patients and society.Sensei Biotherapeutics using its proprietary drug discovery platform to study and understand the tumor microenvironment and identify a new class of cancer immunotherapies that act through new biology and differentiated mechanisms. It brings together scientific leaders in biology, immunology, and oncology along with a highly experienced management team and scientific advisors. The company's platform, ImmunoPhage enables the generation of immune-activating agents that fully engage activation of both the innate and adaptive immune systems. Sensei Biotherapeutics is headquartered in Gaithersburg, Maryland with an office in Boston, MA, USA. | $30M | Series B | Jan 11, 2021 | https://www.senseibio.com/ |
| Sensei Biotherapeutics | Sensei Biotherapeutics is a clinical-stage biotechnology company specializing in the field of next-generation cancer immunotherapies. The company developing novel biologics therapies targeting key components of the immune system for the treatment of cancers of unmet need. They are also focused on the discovery, development, and delivery ofmedicines that alter the treatment landscape and contributing value to patients and society.Sensei Biotherapeutics using its proprietary drug discovery platform to study and understand the tumor microenvironment and identify a new class of cancer immunotherapies that act through new biology and differentiated mechanisms. It brings together scientific leaders in biology, immunology, and oncology along with a highly experienced management team and scientific advisors. The company's platform, ImmunoPhage enables the generation of immune-activating agents that fully engage activation of both the innate and adaptive immune systems. Sensei Biotherapeutics is headquartered in Gaithersburg, Maryland with an office in Boston, MA, USA. | $28.5M | Series A | Oct 07, 2020 | https://www.senseibio.com/ |
| Samsara Therapeutics | Samsara Therapeutics, Inc. is an R&D-stage biopharmaceutical platform company aiming to discover, develop and commercialize therapeutics for the treatment of unmet medical needs and age-related diseases. Samsara's platform is a pipeline for the identification, chemical optimization, and in vivo validation of compounds that extend a healthylifespan. | $3.2M | Seed | Dec 20, 2019 | http://samsaratherapeutics.com |

8 of 8 investments shown.

## Co-investors
- [Future Ventures](https://shizune.co/investors/profile/future-ventures) — VC Fund, 3 deals together
- [Presight Capital](https://shizune.co/investors/profile/presight-capital) — VC Fund, 3 deals together
- [Apeiron Investment Group](https://shizune.co/investors/profile/apeiron-investment-group) — VC Fund, 2 deals together
- [Solve FSHD](https://shizune.co/investors/profile/solve-fshd) — VC Fund, 2 deals together
- [Adage Capital Management](https://shizune.co/investors/profile/adage-capital-management) — VC Fund, 1 deal together
- [Apollo Health Ventures](https://shizune.co/investors/profile/apollo-health-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Cambrian Biopharma invest in?

Cambrian Biopharma invests primarily in Biotechnology, Biopharma and Life Science startups, most often at Series A and Seed stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Cambrian Biopharma?

Public channels for Cambrian Biopharma include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Cambrian Biopharma?

The team at Cambrian Biopharma includes Dennis Yamashita (Executive Vice President, Chemistry), Adrienne Hallett (Vice-President of Global Policy) and Christian Angermayer (Co-Founder), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co